FDA approves first self-administered flu vaccine spray
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the first "self-administered" influenza vaccine — though a delay in the change means the vaccine will not be available to ship to homes until next year's flu season at the earliest.
The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for ...
Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with a landmark FDA approval for its innovative drug, MIPLYFFA, in the ...
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
Moderna has secured FDA approval for its respiratory syncytial ... mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding ...
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...
The U.S. Food and Drug Administration has authorized the first-ever over-the-counter hearing aid software intended to be used ...
The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback